<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931485</url>
  </required_header>
  <id_info>
    <org_study_id>REDUCE</org_study_id>
    <nct_id>NCT04931485</nct_id>
  </id_info>
  <brief_title>Protocolised Early De-Resuscitation in Septic Shock (REDUCE)</brief_title>
  <acronym>REDUCE</acronym>
  <official_title>Protocolised Early De-Resuscitation in Septic Shock (REDUCE) - a Randomised Controlled Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Recent studies have questioned the safety of current fluid resuscitation&#xD;
      strategies in patients with septic shock as prospective and observational data suggesting&#xD;
      that the resulting fluid overload is associated with mortality. Two strategies have evolved&#xD;
      to prevent or minimize fluid overload: restrictive fluid administration or active removal of&#xD;
      accumulated fluid. While several small trials show benefits with a restrictive fluid&#xD;
      administration regimen, active protocolized de-resuscitation was scarcely evaluated. The&#xD;
      combination of both strategies yet warrants systematic evaluation.&#xD;
&#xD;
      Aim: This study aims to assess the efficacy and feasibility of an early active&#xD;
      de-resuscitation protocol in patients with septic shock. We hypothesize that the application&#xD;
      of a structured early de-resuscitation protocol versus standard of care will lead to less&#xD;
      fluid overload at day three after ICU admission.&#xD;
&#xD;
      Study Intervention: Patients admitted to the ICU with confirmed or suspected septic shock&#xD;
      (Sepsis-3 definition) will be randomized (1:1) to either the intervention or standard of&#xD;
      care. In the intervention arm, patients are managed according to the REDUCE fluid management&#xD;
      protocol during resuscitation and de-resuscitation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to receive either fluid resuscitation/de-resuscitation according to the REDUCE protocol or standard of care.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcome assessors will be blinded to the treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patient with a negative fluid balance on day 3</measure>
    <time_frame>Up to day 3 after ICU admission</time_frame>
    <description>Proportion of patients with a negative cumulative fluid balance on day 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with fluid overload at day 3 and ICU discharge</measure>
    <time_frame>From hospital admission to the end of ICU stay, on average after 7 days</time_frame>
    <description>Fluid overload as defined as ((input-output)/admission weight)*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of the REDUCE fluid protocol</measure>
    <time_frame>From randomisation until the end of ICU stay, on average after 7 days</time_frame>
    <description>Number of REDUCE fluid protocol violations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ischemic events and severe AKI</measure>
    <time_frame>Ischemic events and AKI: From randomisation until the end of ICU stay (on average after 7 days), and at day 30; electrolyte and acid-base/medication associated safety endpoints: during ICU stay (on average 7 days)</time_frame>
    <description>Number of patients with:ischaemic events, severe AKI (AKIN stage 2 or more); respectively episodes of: severe hypernatremia (sodium &gt;/= 155mmol/l), severe hypokalemia (&lt; 3.0 mmol/l), severe metabolic alkalosis (pH &gt;/= 7.55, bicarbonate &gt;/= 35 mmol/l), anaphylactic reaction to diuretic drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days at day 30</measure>
    <time_frame>Up to 30 days after randomisation</time_frame>
    <description>Ventilator free days up to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor-free days at day 30</measure>
    <time_frame>Up to 30 days after randomisation</time_frame>
    <description>Vasopressor free days up to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>Up to 90 days after randomisation</time_frame>
    <description>Need for and time on renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with need for renal replacement at 90days</measure>
    <time_frame>Up to 90 days after randomisation</time_frame>
    <description>Number of patients with on-going need for renal replacement at 90days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to 90 days after randomisation</time_frame>
    <description>At 30days and 90 days after randomization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Daily cumulative fluid balance up to day 7</measure>
    <time_frame>Throughout the ICU stay, on average 7 days</time_frame>
    <description>Cumulative fluid balance is total input - total output</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Intervention: REDUCE Protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluid resuscitation and de-resuscitation is based on the REDUCE fluid management protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluid resuscitation and de-resuscitation according to the standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluid management according to the REDUCE Fluid Protocol</intervention_name>
    <description>Fluid management according to the protocol will be guided by pre-defined clinical signs for impaired perfusion and fluid overload.</description>
    <arm_group_label>Intervention: REDUCE Protocol</arm_group_label>
    <other_name>REDUCE protocol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Fluid resuscitation and de-resuscitation will be managed according to the standard of care</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to ICU with the diagnosis of septic shock as defined according to&#xD;
             the Sepsis-3 criteria (suspected or confirmed infection AND vasopressor/inotrope&#xD;
             ongoing to maintain MAP ≥ 65 mmHg AND Lactate ≥ 2 mmol/l in the last 6 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Septic shock for more than 12 hours at the time of screening&#xD;
&#xD;
          -  Acute burn injury &gt;/= 10% of the body surface area&#xD;
&#xD;
          -  Known pregnancy or lactating women&#xD;
&#xD;
          -  Consent not obtainable due to national legislation&#xD;
&#xD;
          -  Patients on chronic dialysis&#xD;
&#xD;
          -  Patients that are known to be allergic to furosemide or metolazone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna S Messmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Intensive Care, Inselspital, Bern University Hospital, Bern, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna S Messmer, MD</last_name>
    <phone>+41316325300</phone>
    <phone_ext>+41316325300</phone_ext>
    <email>anna.messmer@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmen A Pfortmueller, MD</last_name>
    <phone>+41316325300</phone>
    <phone_ext>+41316325300</phone_ext>
    <email>carmen.pfortmueller@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Bern, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna S Messmer, MD</last_name>
      <phone>0041316325300</phone>
      <email>anna.messmer@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Carmen A Pfortmueller, Prof</last_name>
      <phone>0041316325300</phone>
      <email>carmen.pfortmueller@insel.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Fluid resuscitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

